Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The overall frequency of bone fracture was 17.6% (n = 161) in post-menopausal patients and a lower risk for bone fractures was associated with tamoxifen or other treatments (OR: 0.25; 95% CI: 0.12 to 0.53), presence of back pain (OR: 1.65; 95% CI: 1.16 to 2.36), lower BMD (OR: 2.09 in patients with T-score ≤ 2.5; 95% CI: 1.21 to 3.59) and lower vitamin D levels (OR: 1.57 in patients with ≤ 10 ng/mL; 95% CI: 1.05 to 2.34) in univariate analysis.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Methods: Pre: and post-menopausal women undergoing adjuvant endocrine therapy for early-stage BC who came to our institute for their first bone health evaluation from January 2011 to June 2016 were considered in this retrospective observational study.

Source: Abstract.

Patients were asked to complete a self-reporting questionnaire during the visit to collect information on life style factors such as dietary patterns (milk, cheese, yoghurt, vegetables, and water), physical activity (established as at least 30 min/day), presence of back pain, BMD, and previous/current calcium therapy and ET.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study)

Observational study · Journal of Clinical Medicine · 2019

Original publication title

BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study)

Federica Recine; Alberto Bongiovanni; Flavia Foca; Laura Mercatali; Valentina Fausti; Sebastiano Calpona; Nada Riva; Alessandro De Vita; Chiara Liverani; Chiara Spadazzi; Giacomo Miserocchi; Giandomenico Di Menna; Lorena Gurrieri; Claudia Cocchi; Silvia Angela Debonis; Roberto Vespignani; Toni Ibrahim

© 2019 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Background: We assessed the real-life clinical impact of bone health management in patients with breast cancer (BC) receiving adjuvant endocrine therapy at an Italian Osteoncology Center. Methods: Pre: and post-menopausal women undergoing adjuvant endocrine therapy for early-stage BC who came to our institute for their first bone health evaluation from January 2011 to June 2016 were considered in this retrospective observational study. Results: 1125 pre: and post-menopausal early-stage BC patients (209 and 916, respectively) were evaluated. Median age was 61 years (range 26 to 88).

In the pre-menopausal group, spinal x-ray revealed that 10 patients (4.7%) had a morphometric vertebral fracture. Higher age (OR: 1.14; 95% CI: 1.01 to 1.29) and bone mineral density (BMD) ≤ −2.5 (OR: 14.45; 95% CI: 1.70 to 122.67) were associated with a higher risk of bone fracture. The overall frequency of bone fracture was 17.6% (n = 161) in post-menopausal patients and a lower risk for bone fractures was associated with tamoxifen or other treatments (OR: 0.25; 95% CI: 0.12 to 0.53), presence of back pain (OR: 1.65; 95% CI: 1.16 to 2.36), lower BMD (OR: 2.09 in patients with T-score ≤ 2.5; 95% CI: 1.21 to 3.59) and lower vitamin D levels (OR: 1.57 in patients with ≤ 10 ng/mL; 95% CI: 1.05 to 2.34) in univariate analysis.

Conclusion: Our findings confirm that bone health management should be an integral part of long-term cancer care.

Authors’ abstract

Background: We assessed the real-life clinical impact of bone health management in patients with breast cancer (BC) receiving adjuvant endocrine therapy at an Italian Osteoncology Center. Methods: Pre: and post-menopausal women undergoing adjuvant endocrine therapy for early-stage BC who came to our institute for their first bone health evaluation from January 2011 to June 2016 were considered in this retrospective observational study. Results: 1125 pre: and post-menopausal early-stage BC patients (209 and 916, respectively) were evaluated. Median age was 61 years (range 26 to 88).

In the pre-menopausal group, spinal x-ray revealed that 10 patients (4.7%) had a morphometric vertebral fracture. Higher age (OR: 1.14; 95% CI: 1.01 to 1.29) and bone mineral density (BMD) ≤ −2.5 (OR: 14.45; 95% CI: 1.70 to 122.67) were associated with a higher risk of bone fracture. The overall frequency of bone fracture was 17.6% (n = 161) in post-menopausal patients and a lower risk for bone fractures was associated with tamoxifen or other treatments (OR: 0.25; 95% CI: 0.12 to 0.53), presence of back pain (OR: 1.65; 95% CI: 1.16 to 2.36), lower BMD (OR: 2.09 in patients with T-score ≤ 2.5; 95% CI: 1.21 to 3.59) and lower vitamin D levels (OR: 1.57 in patients with ≤ 10 ng/mL; 95% CI: 1.05 to 2.34) in univariate analysis.

Conclusion: Our findings confirm that bone health management should be an integral part of long-term cancer care.

Publication and source details

Original title: BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study)

Federica Recine; Alberto Bongiovanni; Flavia Foca; Laura Mercatali; Valentina Fausti; Sebastiano Calpona; Nada Riva; Alessandro De Vita; Chiara Liverani; Chiara Spadazzi; Giacomo Miserocchi; Giandomenico Di Menna; Lorena Gurrieri; Claudia Cocchi; Silvia Angela Debonis; Roberto Vespignani; Toni Ibrahim

Journal of Clinical Medicine · 2019

* Correspondence: federica.recine@irst.emr.it; Tel.: +39-0543-739140; Fax: +39-0543-739151© 2019 by the authors.2019https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T18:48:15.584886+00:00

DOI: 10.3390/jcm8111894 · PMC6912302